Followers | 4 |
Posts | 243 |
Boards Moderated | 0 |
Alias Born | 05/31/2008 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, September 01, 2011 12:13:53 PM
"One can be infected with H1N1 and 5 years later a new H1N1 poses a threat. What then? Use the H1N1 DRACO and it will kill all the healthy cells that survived the previous infection. Is this really a slam dunk similar to targeting only viruses?"
I have two questions:
(1) It seems to me that Draco is broad spectrum, that is it will attack all cells that are virus infected. So that means there is no H1N1 Draco, there is only one Draco. Regarding your post, Draco will kill all virus infected cells, not virus immune cells. The cells that have become immune to previous H1N1 are immune cells not cells with previous H1N1 virus. So why would Draco kill those?
(2) The question of toxicity still haunts me. Our viricides have been claimed to have no toxicity. However, I have only seen only one publication which is about the Ebola virus. That poster said that there was a small amount of toxicity to viricides. So how comfortable are you with the claim that viricides have no toxicity?
I have not posted in a few weeks. After my last series of posts I had a phone call with Dr. Seymour and now I feel much more comfortable with investing in NNVC. I have subsequently doubled my position. More or less it is NNVCs lack of money that has created the slow pace. They are now prepared to go much more rapidly. That still remains to be seen. It seems that Seymour would have already filed the IND, the only reason it is being delayed is that they have been told to be super careful since they only get one chance with this filing. Seems like a prudent thing to do, but there is a limit to being prudent. One has to go forward, you cannot be so careful that the pace become glacial. At every stage we will get only one chance to file (IND, phase 1, phase 2, phase 3, NDA etc.)
Seeker
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM